Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity

British Journal of Ophthalmology

Volumn 97, Issue 7, 2013, Pages 816-819

  Castellanos, María Ana Martínez ^a   Schwartz, Shulamit ^b   García Aguirre, Gerardo ^a   Quiroz Mercado, Hugo ^b  

^a HOSPITAL DR LUIS SÁNCHEZ BULNES   (Mexico)

^b DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ARTICLE; CASE REPORT; DRUG EFFICACY; EYE TOXICITY; FEMALE; FOLLOW UP; HUMAN; INFANT; INTERVENTION STUDY; MALE; MONOTHERAPY; OFF LABEL DRUG USE; OPHTHALMOSCOPY; OUTCOME ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; RETINA DEVELOPMENT; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; SYSTEMIC DISEASE; TREATMENT DURATION; VISUAL ACUITY;

CHILD HEALTH (PAEDIATRICS); RETINA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIRTH WEIGHT; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTRAVITREAL INJECTIONS; MALE; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84879415929     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302276     Document Type: Article

References (22)

1. Lad EM, Hernandez-Boussard T, Morton JM, et al. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol 2009;148:451-8.
2. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84:77-82.
3. Smith LE . Through the eyes of a child: understanding retinopathy through ROP. Invest Ophthalmol Vis Sci 2008;49:5177-82.
4. Villegas B, Gonzalez F, Fernandez M. Growth factor levels and ROP. Ophthalmology 2005;112:2238.
5. Stone J, Chan-Ling T, Pe'er J, et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996;37:290-9.
6. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol 1988;106:471-9.
7. Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004;102:233-48.
8. Kimoto K, Kubota T. Anti-VEGF agents for ocular angiogenesis and vascular permeability. J Ophthalmol 2012;2012:852183.
9. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28:S19-25.
10. Lalwani G, Berrocal A, Murray T, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008;28:S13-18.
11. Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos MA, et al. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Semin Ophthalmol 2007;22:109-25.
12. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-15.
13. Mota A, Carneiro A, Breda J, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Report Ophthalmol 2012;3:136-41.
14. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991-9.
15. Zepeda-Romero LC, Barrera-de-Leon JC, Camacho-Choza C, et al. Retinopathy of prematurity as a major cause of severe visual impairment and blindness in children in schools for the blind in Guadalajara city, Mexico. Br J Ophthalmol 2011;95:1502-5.
16. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94.
17. Laws F, Laws D, Clark D. Cryotherapy and laser treatment for acute retinopathy of prematurity: refractive outcomes, a longitudinal study. Br J Ophthalmol 1997;81:12-15.
18. Cuthbertson F, Nerwsom R. UK retinopathy of prematurity treatment survey. Eye 2006;7:76-81.
19. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009;148:536-43.
20. Darlow BA, Ells AL, Gilbert CE, et al. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. Published Online First: 30 Dec 2011. doi:0.1136/archdischild-2011-301148.
21. Castellanos MA, Schwartz S, Leal R, et al. Pain assessment in premature infants treated with intravitreal antiangiogenic therapy for retinopathy of prematurity under topical anesthesia. Graefes Arch Clin Exp Ophthalmol 2012. (Epub ahead of print).
22. Bressler SB. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009;116(10 Suppl):S1-7.